Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CGM097 |
Trade Name | |
Synonyms | NVP-CGM097 |
Drug Descriptions |
CGM097 binds to the p53 binding region of MDM2 and prevents MDM2-p53 interaction, resulting in activation of p53 signaling and decreased tumor growth (Cancer Res October 1, 2014 74:4638, PMID: 32651541). |
DrugClasses | MDM2 Inhibitor 23 |
CAS Registry Number | 1313363-54-0 |
NCIT ID | C104280 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Alpelisib + CGM097 + Navitoclax + Trametinib | Alpelisib CGM097 Navitoclax Trametinib | 0 | 0 |
Ceritinib + CGM097 | CGM097 Ceritinib | 3 | 0 |
CGM097 | CGM097 | 0 | 1 |
CGM097 + Dabrafenib + Navitoclax + PF-04217903 | CGM097 Dabrafenib Navitoclax PF-04217903 | 1 | 0 |
CGM097 + Encorafenib | CGM097 Encorafenib | 1 | 0 |
CGM097 + Navitoclax + Trametinib | CGM097 Navitoclax Trametinib | 0 | 0 |
CGM097 + Sotrastaurin | CGM097 Sotrastaurin | 0 | 0 |
CGM097 + Trametinib | CGM097 Trametinib | 0 | 0 |
CGM097 + Venetoclax | CGM097 Venetoclax | 0 | 0 |